CSF3 and neutropenia: The AHCC group had significantly fewer neutrophil related events and less use of granulocyte colony-stimulating factor. The treatment group also experienced a higher (non-significant) rate of adverse events associated with c-glutamyl transpeptidase. AHCC may be able to lower the severity of neutropenia stemming from chemotherapy (including granulocyte-colony stimulating factor use during chemotherapy; AHCC also showed promise in lowering the toxicity of chemotherapy, allowing for increase in dosage breast cancer patients receiving chemotherapy.